Unethical marketing practices in the pharmaceutical sector undermine rational drug use and patient trust. Discuss with reference to UCPMP 2024.

Prescription in India is a fiduciary act, yet aggressive promotion — gifts, hospitality and sponsored travel routed to doctors — converts it into a commercial transaction. The Uniform Code of Pharmaceuticals Marketing Practices (UCPMP) 2024, notified by the Department of Pharmaceuticals on 12.03.2024 [1], seeks to restore ethical balance in doctor–industry interactions.

How unethical promotion distorts rational drug use

• Inducement-driven prescribing: gifts and monetary benefits to doctors and their family members bias drug choice toward the highest-margin brand rather than the clinically optimal one — hence their explicit prohibition [1].
• Brand capture over generics: promotional pressure works against generic prescribing, which the IMC (Professional Conduct) Regulations, 2002 mandate in capital letters [1].
• Disguised promotion: conferences, seminars and CME/CPD events can become marketing vehicles, which is why UCPMP requires disclosure of expenditure on them [1].

Erosion of patient trust

• Perceived conflict of interest weakens confidence in medical advice; promotional costs are ultimately passed on to patients as higher out-of-pocket spending.
• Accountability was weak earlier: UCPMP 2015 operated from 01.01.2015 as a purely voluntary code enforced by industry associations themselves [2], with the Government relying on association-level ethics committees [3].

UCPMP 2024 as a corrective

• Institutional machinery: association-level Ethics Committees for Pharmaceutical Marketing Practices (ECPMP), with appeals to an Apex Committee headed by the Secretary, Department of Pharmaceuticals [4].
• Transparency: self-declaration of compliance and publication of complaint details on association websites [4].
• Deterrence: recovery of money or items given in violation, corrective media statements, and referral for action under existing laws [1].

Remaining gap: it is still a Code, not a statute, so penal force depends on other laws.

UCPMP 2024 thus shifts pharmaceutical marketing from self-regulation towards supervised accountability. Placing it on a statutory footing, linking violations to tax and licensing consequences, and strengthening generic-drug promotion through Jan Aushadhi would complete the transition — ensuring that the right to health under Article 21 is served by evidence, not by inducement.